Our T-cellerator technology enables us to generate patient-derived (autologous) expanded T cells specific to Epstein-Barr virus (EBV), our CMD-003 product, and adapt the cells to express improved functionality even in the hostile micro-environment of a tumor. This technology has the potential to be adapted to a variety of additional viral targets and is currently being tested against human papilloma viruses (HPV) with our CMD-004 program.
The manufacturing process starts with the isolation of peripheral blood mononuclear cells (PBMCs) from a patient-derived whole blood sample. T cells in the PBMC fraction are then stimulated with autologous dendritic cells (DCs) and overlapping peptide pools of EBV antigens.
The process also involves expansion steps to obtain cell numbers sufficient for clinical applications and utilises additional cell types such as DCs and also cytokines.
The final product is formulated, cryopreserved and stored prior to shipment to the clinical site for infusion.